期刊文献+
共找到3篇文章
< 1 >
每页显示 20 50 100
尿毒清胶囊对慢性肾功能衰竭患者肾纤维化指标的影响 被引量:10
1
作者 张秋林 洪钦国 《广州中医药大学学报》 CAS 2007年第2期108-112,共5页
【目的】观察升清泄浊法中药制剂尿毒清胶囊(由附子、黄芪、大黄、法半夏、土茯苓等组成)对慢性肾功能衰竭(CRF)患者的临床疗效及其抗肾纤维化的作用。【方法】用简单随机化、前瞻性的研究方法,将78例慢性肾功能衰竭患者按1∶1分为治疗... 【目的】观察升清泄浊法中药制剂尿毒清胶囊(由附子、黄芪、大黄、法半夏、土茯苓等组成)对慢性肾功能衰竭(CRF)患者的临床疗效及其抗肾纤维化的作用。【方法】用简单随机化、前瞻性的研究方法,将78例慢性肾功能衰竭患者按1∶1分为治疗组和对照组。两组均给予低优质蛋白饮食、血压控制、纠正水电解质紊乱和酸碱平衡、利尿剂的使用、抗感染等基本治疗,治疗组在基本治疗的基础上加服尿毒清胶囊,对照组在基本治疗基础上加服包醛氧淀粉,两组均以4周为1个疗程,连续治疗2个疗程后统计结果。观察患者主要症状、证候和血红蛋白(Hb)、红细胞总数(RBC)、血清肌酐(SCr)、尿素氮(BUN)、内生肌酐清除率(CCr)、血清白蛋白(ALB)、血清总胆固醇(TCh)、甘油三酯(TG)、低密度脂蛋白—胆固醇(LDL-C)、高密度脂蛋白—胆固醇(HDL-C)、血清层粘蛋白(LN)、Ⅲ型前胶原(PC-Ⅲ)、透明质酸(HA)等实验室检测指标的变化情况。【结果】治疗组主要症状总计分、大部分症状单项计分均少于对照组(P<0.05或P<0.01),症状疗效和总体疗效均高于对照组(P<0.05或P<0.01);尿毒清胶囊能提高CRF患者血清ALB、HDL-C、CCr水平,降低TCh、TG、LDL-C、BUN、SCr、LN、PC-Ⅲ、HA水平(P<0.05或P<0.01),但对RBC、Hb的升高作用与对照组比较无显著性差异(P>0.05)。【结论】中药升清泄浊法制剂尿毒清胶囊不仅能改善患者临床症状,而且能改善患者的肾功能;对肾纤维化指标也有改善作用,说明该药具有良好的抗肾纤维化作用。 展开更多
关键词 肾纤维化/中药疗法 尿毒清胶囊/治疗应用
下载PDF
Effectiveness of Jinying capsule on pelvic inflammatory disease in patients with symptom pattern of damp and heat accumulation: a double-blinded, multicenter, randomized, placebo-controlled clinical trial 被引量:11
2
作者 Yang Yan Lu Yao +7 位作者 Zhou Deping Pei Fenglan Li Qin Chen Shuqiong Wang Qiufeng Wang Yanting Jin Zhe Liu Yanxia 《Journal of Traditional Chinese Medicine》 SCIE CAS CSCD 2020年第3期432-439,共8页
OBJECTIVE: To evaluate the therapeutic effectiveness and safety of Jinying capsule on pelvic inflammatory disease(PID) in patients with symptoms identified as the pattern of damp and heat accumulation in terms of Trad... OBJECTIVE: To evaluate the therapeutic effectiveness and safety of Jinying capsule on pelvic inflammatory disease(PID) in patients with symptoms identified as the pattern of damp and heat accumulation in terms of Traditional Chinese Medicine(TCM).METHODS: We conducted a double-blinded, multicenter, randomized, placebo-controlled clinical trial which included 155 patients diagnosed with PID and identified as symptom pattern of damp and heat accumulation. They were randomly divided into experimental group(n = 78) and control group(n = 77) according to a random number table. The treatment lasted for a period of 28 d. The experimental group was given Jinying capsules and oral levofloxacin plus oral metronidazole for first 7 d.They continued with Jinying capsules and levofloxacin placebo and metronidazole placebo for another 7 d. For the remaining 14 d, they continued with Jinying capsules only. Whereas, the control group was treated with oral levofloxacin and metronidazole and Jinying capsule placebo for the first 14 d in the same way as the experimental group and then continued with Jinying capsule placebo only for the remaining 14 d. The clinical efficacy was assessed using McCormack scale, TCM symptom pattern scores, physicochemical indexes including white blood cell and erythrocyte sedimentation rate, C-reaction protein, smear of vaginal discharge,and pelvic ultrasound.RESULTS: Comparing McCormack scale between both groups after treatment, the difference in curative effect between both groups was significant (P = 0.0269). The cure rate of the experimental group and control group is 76.32% and 59.46% respectively at week 4. Comparing TCM symptom pattern scores between both groups before and after treatment, the differences in total effective rate were both significant(P < 0.05). The curative effect rate of experimental group is 2.63% and 13.70% of the control group at week 1(P = 0.0131), and73.33% of the experimental group and 56.94% of the control group at week 4(P = 0.0369). No significant differences were found between the two groups on the Physicochemical indexes(all P >0.05). No adverse events or reactions occurred in the experimental groups.CONCLUSION: Jinying capsule can reduce the dosage of antibiotics needed for PID treatment, and improve the symptoms in PID patients. 展开更多
关键词 Pelvic inflammatory disease Dampness-heat therapeutic uses Safety Randomized controlled trial Double-blind method Jinying capsule
原文传递
黄葵胶囊联合尿毒清用于肾功能不全患者的临床效果 被引量:5
3
作者 谢莹莹 夏燕 +2 位作者 张雪梅 潘颖 王东 《世界中医药》 CAS 2021年第10期1581-1583,1588,共4页
目的:探析采取黄葵胶囊联合尿毒清治疗肾功能不全患者的有效性。方法:选取2019年1月至2020年6月马鞍山十七治医院收治的肾功能不全患者60例作为研究对象进行回顾性分析,按照治疗方法不同分成对照组和观察组,每组30例。对照组采用常规西... 目的:探析采取黄葵胶囊联合尿毒清治疗肾功能不全患者的有效性。方法:选取2019年1月至2020年6月马鞍山十七治医院收治的肾功能不全患者60例作为研究对象进行回顾性分析,按照治疗方法不同分成对照组和观察组,每组30例。对照组采用常规西医治疗,观察组给予黄葵胶囊联合尿毒清治疗,比较2组患者血红蛋白(Hb)水平、红细胞计数(RBC)、尿素氮(BUN)、血肌酐(SCr)、不良反应及治疗有效率等指标。结果:与对照组比较,观察组Hb、RBC、BUN、SCr等生化指标改善更明显,差异有统计学意义(P<0.05);观察组不良反应发生率更低,治疗有效率更高,差异有统计学意义(P<0.05)。结论:采取黄葵胶囊联合尿毒清颗粒治疗肾功能不全能够获得较为理想的效果,用药安全性较高,有极大的推广价值。 展开更多
关键词 肾功能不全 黄葵胶囊 尿毒清 不良反应 生化指标 安全性 肾功能 治疗效果
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部